GHK-Cu Peptide

## What it is GHK is a naturally occurring tripeptide composed of glycine, histidine, and lysine, first isolated from human plasma by Loren Pickart in 1973. It binds Cu(II) with high affinity to form GHK-Cu, the bioactive complex with most documented activity. Endogenous plasma GHK declines from approximately 200 ng/mL in young adults to roughly 80 ng/mL by age 60, a 60% drop that has fueled the pitch as an age-related repair signal worth restoring. GHK-Cu has a long history in topical cosmetics: it has been included in dermatology and skincare formulations since the 1980s, with peer-reviewed RCT support for fine-line reduction, skin barrier function, and wound healing. Injectable use is a more recent and far more speculative application driven by Pickart's gene-expression analyses and biohacker community protocols. The tripeptide is not approved as an injectable drug in any jurisdiction. Topical cosmetic use is generally legal; injectable use sits in the research-peptide grey market and carries the same regulatory ambiguity as other unapproved peptides. ## Mechanism of action GHK-Cu functions primarily as a copper-delivery vehicle and a transcriptional modulator. The tripeptide chelates Cu(II) and delivers it intracellularly to copper-dependent enzymes including lysyl oxidase (involved in collagen and elastin crosslinking), superoxide dismutase 3, and tyrosinase. This restores activity of enzymes that depend on adequate intracellular copper, which can become limiting in aged or wounded tissue. Beyond copper delivery, GHK-Cu modulates expression of more than 4000 genes in fibroblast cell culture, with a directional pattern Pickart and colleagues describe as a partial reset toward a younger expression profile. Notable changes include upregulation of decorin (a small leucine-rich proteoglycan involved in tissue organization), downregulation of pro-inflammatory cytokines including TNF-alpha, and modulation of DNA repair pathways. Plasma half-life of injected GHK-Cu is short, around 30 minutes, but topical reservoir effects within the stratum corneum and dermal layers persist for hours to days. ## Evidence base Topical evidence is the strongest. Multiple peer-reviewed RCTs over 8 to 12 weeks document improvements in skin firmness, fine-line depth, and barrier function in photoaged skin. A Leyden 2002 study (n=67) showed measurable reduction in fine-line depth and improvement in skin appearance versus vehicle control over 12 weeks of twice-daily topical application. Finkley 2005 reported improved transepidermal water loss and barrier integrity in healthy adult skin over 12 weeks. Wound-healing evidence is modest. Animal studies and a handful of small human trials have reported accelerated re-epithelialization in diabetic ulcers and post-surgical wounds, with effect sizes comparable to other peptide and growth-factor topicals. The Mulder 1994 diabetic ulcer trial (n=120) showed faster closure rates with copper-peptide topical formulations versus standard care. Hair-growth evidence is weaker: 2 small open-label trials (n=80 combined) reported modest density gains in mild androgenetic alopecia over 6 months of topical scalp application. The effect size is well below that of finasteride or minoxidil and the trials lack rigorous controls. The injectable longevity narrative is the weakest link in the evidence chain. Pickart's gene-expression analyses are conducted in fibroblast cell culture, not in living humans. There are no completed human longevity outcome trials for injected GHK-Cu, and no controlled human data on subcutaneous dosing for any indication. Anecdotal reports of improved sleep, mood, and joint comfort exist but are not validated. ## Dosage and administration Topical formulations range from 0.05% to 3%, applied 1 to 2 times daily. Cosmetic OTC products typically contain 0.05% to 0.5%, while research-grade RCT formulations often used 2% to 3%. Effects accumulate over 8 to 12 weeks. Stack with niacinamide is unproblematic; stack with strong retinoids or ascorbic acid (vitamin C) requires temporal separation, as ascorbate reduces Cu(II) to Cu(I) and can destabilize the chelate. Anecdotal injectable protocols use 1 to 3 mg subcutaneously daily, often run for 4 to 8 weeks then off. A typical 50 mg vial reconstituted with 2 mL bacteriostatic water gives 25 mg/mL; a 2 mg dose equals 8 units on a U100 insulin syringe. Reconstituted GHK-Cu is characteristically blue-green from the copper chromophore; a faded or colorless solution suggests displacement of the copper ion and loss of the active complex. Reference the typicalDoseMg of 2 and the daily frequency for orientation. Cycling is anecdotal; topical use is continuous. ## Side effects and safety Topical adverse effects are usually mild: erythema at application site, transient itch, and rare contact dermatitis. Injectable users report blue-green discoloration at the injection site that fades over hours, mild local irritation, and rare systemic effects such as transient flushing. Long-term injectable safety is unestablished. Contraindications include known copper allergy, Wilson disease (a hereditary copper-overload disorder), and pregnancy due to absent safety data on injected forms. Topical use in pregnancy is generally considered low-risk but has not been formally studied. Drug interactions: topical retinoids amplify irritation acutely, so alternate days or apply at different times of day; topical ascorbic acid reduces the copper(II) center, so separate by 30 minutes minimum. ## Practical notes Lyophilized GHK-Cu is stable at room temperature but is best refrigerated. Reconstituted solution should be refrigerated and used within 2 to 4 weeks. The blue-green color of fresh solution is the simplest visual quality check; a clear or pale solution suggests degradation. Topical formulations should be stored in opaque containers as the complex is light-sensitive. Expect topical skin-quality changes over 8 to 12 weeks, with most users reporting visible smoothing and barrier improvement by week 6. Hair-density changes, if they occur, accumulate over 4 to 6 months. Injectable users describe subjective benefits (sleep, mood, joint comfort) within 1 to 2 weeks, but the absence of controlled human data means individual outcomes are not distinguishable from placebo, regression, or natural variation. Pair topical GHK-Cu with sunscreen and a basic retinoid regimen if anti-aging is the goal; the additive effect on photoaged skin is more meaningful than either alone.